BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berzigotti A, Bosch J. Pharmacologic management of portal hypertension. Clin Liver Dis. 2014;18:303-317. [PMID: 24679496 DOI: 10.1016/j.cld.2013.12.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Yao H, Zhang C. Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials. Ir J Med Sci 2018;187:925-34. [DOI: 10.1007/s11845-018-1765-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Garbuzenko DV. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis. World J Gastroenterol 2015; 21(20): 6117-6126 [PMID: 26034348 DOI: 10.3748/wjg.v21.i20.6117] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
3 Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol. 2015;62:S121-S130. [PMID: 25920081 DOI: 10.1016/j.jhep.2015.01.003] [Cited by in Crossref: 112] [Cited by in F6Publishing: 92] [Article Influence: 18.7] [Reference Citation Analysis]
4 Yoon JH, Lee JM, Yu MH, Hur BY, Grimm R, Sourbron S, Chandarana H, Son Y, Basak S, Lee KB, Yi NJ, Lee KW, Suh KS. Simultaneous evaluation of perfusion and morphology using GRASP MRI in hepatic fibrosis. Eur Radiol 2021. [PMID: 34120229 DOI: 10.1007/s00330-021-08087-2] [Reference Citation Analysis]
5 Kennedy P, Bane O, Hectors SJ, Fischman A, Schiano T, Lewis S, Taouli B. Noninvasive imaging assessment of portal hypertension. Abdom Radiol 2020;45:3473-95. [DOI: 10.1007/s00261-020-02729-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bunchorntavakul C, Reddy KR. Pharmacologic Management of Portal Hypertension. Clin Liver Dis 2019;23:713-36. [PMID: 31563219 DOI: 10.1016/j.cld.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yao Q, Chen W, Yan C, Yu J, Jiang T, Cao H. Efficacy and Safety of Treatments for Patients With Portal Hypertension and Cirrhosis: A Systematic Review and Bayesian Network Meta-Analysis. Front Med (Lausanne) 2021;8:712918. [PMID: 34540867 DOI: 10.3389/fmed.2021.712918] [Reference Citation Analysis]
8 Sanz-garcía C, Fernández-iglesias A, Gracia-sancho J, Arráez-aybar LA, Nevzorova YA, Cubero FJ. The Space of Disse: The Liver Hub in Health and Disease. Livers 2021;1:3-26. [DOI: 10.3390/livers1010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
9 Garbuzenko DV, Arefyev NO, Kazachkov EL. Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives. World J Gastroenterol 2018; 24(33): 3738-3748 [PMID: 30197479 DOI: 10.3748/wjg.v24.i33.3738] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. Expert Opin Emerg Drugs 2016;21:167-81. [PMID: 27148904 DOI: 10.1080/14728214.2016.1184647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
11 Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A, Deibert P. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int J Mol Sci 2020;21:E6223. [PMID: 32872119 DOI: 10.3390/ijms21176223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Garbuzenko DV. [Aspects of pathogenetc pharmacotherapy for portal hypertension in liver cirrhosis]. Ter Arkh. 2016;88:101-108. [PMID: 27135108 DOI: 10.17116/terarkh2016888101-108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Boyer-Diaz Z, Morata P, Aristu-Zabalza P, Gibert-Ramos A, Bosch J, Gracia-Sancho J. Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical. Nutrients 2020;12:E2627. [PMID: 32872239 DOI: 10.3390/nu12092627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017. Liver Int. 2017;37 Suppl 1:104-115. [PMID: 28052623 DOI: 10.1111/liv.13277] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 7.4] [Reference Citation Analysis]
15 Khor S, Cai D. Hypothalamic and inflammatory basis of hypertension. Clin Sci (Lond) 2017;131:211-23. [PMID: 28057892 DOI: 10.1042/CS20160001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Snyder P, Ali R, Poles M, Gross SA. Portal hypertensive gastropathy with a focus on management. Expert Rev Gastroenterol Hepatol. 2015;9:1207-1216. [PMID: 26293979 DOI: 10.1586/17474124.2015.1059275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
17 Ferrarese A, Zanetto A, Germani G, Burra P, Senzolo M. Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol 2016; 8(24): 1012-1018 [PMID: 27648153 DOI: 10.4254/wjh.v8.i24.1012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Lunova M, Frankova S, Gottfriedova H, Senkerikova R, Neroldova M, Kovac J, Kieslichova E, Lanska V, Sticova E, Spicak J, Jirsa M, Sperl J. Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis. Physiol Res 2021;70:563-77. [PMID: 34062072 DOI: 10.33549/physiolres.934626] [Reference Citation Analysis]
19 Huang Y, Wang M, Wang J. Hyponatraemia induced by terlipressin: a case report and literature review. J Clin Pharm Ther 2015;40:626-8. [PMID: 26573870 DOI: 10.1111/jcpt.12335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
20 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
21 Vespasiani-Gentilucci U, Rombouts K. Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension. Gut 2015;64:523-4. [PMID: 24966286 DOI: 10.1136/gutjnl-2014-307583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Garbuzenko DV, Arefyev NO. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature. J Evid Based Med 2020;13:313-24. [PMID: 33037792 DOI: 10.1111/jebm.12407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gracia-sancho J, Marrone G, Fernández-iglesias A. Hepatic microcirculation and mechanisms of portal hypertension. Nat Rev Gastroenterol Hepatol 2019;16:221-34. [DOI: 10.1038/s41575-018-0097-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 13.5] [Reference Citation Analysis]
24 Kang SH, Lee M, Kim MY, Lee JH, Jun BG, Kim TS, Choi DH, Suk KT, Kim YD, Cheon GJ, Kim DJ, Baik SK. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatol Int 2021;15:424-36. [PMID: 33860898 DOI: 10.1007/s12072-021-10160-3] [Reference Citation Analysis]